ZA200301865B - New treatments for restless legs syndrome. - Google Patents

New treatments for restless legs syndrome. Download PDF

Info

Publication number
ZA200301865B
ZA200301865B ZA200301865A ZA200301865A ZA200301865B ZA 200301865 B ZA200301865 B ZA 200301865B ZA 200301865 A ZA200301865 A ZA 200301865A ZA 200301865 A ZA200301865 A ZA 200301865A ZA 200301865 B ZA200301865 B ZA 200301865B
Authority
ZA
South Africa
Prior art keywords
substance
composition
treatment
compound
day
Prior art date
Application number
ZA200301865A
Other languages
English (en)
Inventor
Sylvia Mcbrinn
Richard W Anderson
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of ZA200301865B publication Critical patent/ZA200301865B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Fats And Perfumes (AREA)
ZA200301865A 2000-10-31 2003-03-06 New treatments for restless legs syndrome. ZA200301865B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24466600P 2000-10-31 2000-10-31

Publications (1)

Publication Number Publication Date
ZA200301865B true ZA200301865B (en) 2004-06-25

Family

ID=22923642

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200301865A ZA200301865B (en) 2000-10-31 2003-03-06 New treatments for restless legs syndrome.

Country Status (18)

Country Link
US (2) US6602868B2 (fr)
EP (1) EP1330248A2 (fr)
JP (1) JP2004512367A (fr)
KR (1) KR20030042037A (fr)
CN (1) CN1606442A (fr)
AR (1) AR031152A1 (fr)
AU (1) AU2002211226A1 (fr)
BR (1) BR0115071A (fr)
CA (1) CA2421705A1 (fr)
EA (1) EA200300527A1 (fr)
IL (1) IL155591A0 (fr)
MX (1) MXPA03003912A (fr)
NO (1) NO20031923L (fr)
NZ (1) NZ525574A (fr)
PE (1) PE20020514A1 (fr)
PL (1) PL360904A1 (fr)
WO (1) WO2002036123A2 (fr)
ZA (1) ZA200301865B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2314893C (fr) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Combinaison d'agonistes et d'antagonistes d'opioides
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
EP1492506B2 (fr) * 2002-04-05 2016-06-29 Euro-Celtique S.A. Matrice pour liberation prolongee, constante et independante de composes actifs
US20050079217A1 (en) * 2002-07-25 2005-04-14 Ganorkar Loksidh D. Sustained-release tablet composition comprising a dopamine receptor agonist
CA2500919A1 (fr) * 2002-10-04 2004-04-22 Pharmacia Corporation Compositions et methodes permettant le traitement des dysfonctions sexuelles
CN1728998A (zh) * 2002-10-25 2006-02-01 法玛西雅厄普约翰有限责任公司 杂环胺类化合物作为神经保护剂的用途
BRPI0414481A (pt) 2003-09-17 2006-11-14 Xenoport Inc métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
EP1604666A1 (fr) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
EP1604667A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement des impatiences des membres inférieurs
AU2006208627B8 (en) * 2005-01-28 2009-08-13 Mundipharma Pty Limited Alcohol resistant dosage forms
EP1695700A1 (fr) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Forme posologique contenant de l'oxycodone et de la naloxone
EP1702558A1 (fr) 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
WO2007006677A1 (fr) 2005-07-13 2007-01-18 F. Hoffmann-La Roche Ag Derives de benzimidazole tels que 5-ht6, 5-ht24
US20100168119A1 (en) * 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
US8690933B2 (en) * 2009-08-31 2014-04-08 Brigham Young University System and method for treating symptoms of restless legs syndrome
ES2579853T3 (es) * 2010-09-20 2016-08-17 A.Carlsson Research Ab Compuestos de fenilpiperidina para el tratamiento de demencia
EP2950799B1 (fr) 2013-01-30 2019-12-04 Pharmorx Therapeutics, Inc. Traitement de la dépression et autres maladies avec un agent à faible dose
CA2918004C (fr) 2013-07-23 2018-11-20 Euro-Celtique S.A. Combinaison d'oxycodone et de naloxone pour utilisation dans le traitement de la douleur chez des patients souffrant de douleur et d'une maladie entrainant une dysbiose intestinale et/ou l'augmentation du risque de translocation bacterienne intestinale
WO2017034994A1 (fr) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition et procédés d'utilisation de nouveaux petits composés organiques de phénylalanine pour moduler directement l'activité de la protéine pcsk9
EP3337564A4 (fr) 2015-08-21 2019-01-23 Portola Pharmaceuticals, Inc. Composition et procédés d'utilisation de petites molécules de type tétrahydroisoquinoline pour se lier à pcsk9 et moduler l'activité protéique de pcsk9
EP3337788A4 (fr) 2015-08-21 2019-03-27 Portola Pharmaceuticals, Inc. Modulateurs phénylpipérazine proprotéine convertase subtilisine/kexine de type 9 (pcsk9) et leur utilisation
WO2017147328A1 (fr) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Composés se liant à la proprotéine convertase subtilisine/kexine de type 9 (pcsk9)
WO2018129351A1 (fr) 2017-01-05 2018-07-12 Shriram Raghunathan Traitement du syndrome des jambes sans repos ou de l'hyperactivité nerveuse
WO2021067751A1 (fr) 2019-10-03 2021-04-08 Noctrix Health, Inc. Stimulation des nerfs périphériques pour le syndrome des jambes sans repos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
EP0641320B1 (fr) 1991-04-17 2001-05-30 PHARMACIA & UPJOHN COMPANY Derives de (s)-3-phenylpiperidine substitues, leur preparation et leur utilisation comme dopamine autorecepteur antagonistes
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US6001861A (en) 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
BR9908953A (pt) 1998-03-27 2000-12-05 Upjohn Co Utilização de cabergolina no tratamento da sìndrome de pernas agitadas (sìndrome de ekbom)
SE9802546D0 (sv) * 1998-07-15 1998-07-15 Ross Nicholas Waters Medicinal product and method for treatment and prevention of dyskinesia
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
NZ522112A (en) * 2000-04-21 2004-10-29 Upjohn Co Substituted phenylazacycloalkane-type compounds for treating fibromyalgia and chronic fatigue syndrome
AR033520A1 (es) * 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona

Also Published As

Publication number Publication date
NZ525574A (en) 2004-12-24
BR0115071A (pt) 2003-07-29
PL360904A1 (en) 2004-09-20
KR20030042037A (ko) 2003-05-27
EP1330248A2 (fr) 2003-07-30
IL155591A0 (en) 2003-11-23
US6602868B2 (en) 2003-08-05
NO20031923L (no) 2003-06-27
JP2004512367A (ja) 2004-04-22
NO20031923D0 (no) 2003-04-29
PE20020514A1 (es) 2002-06-12
US20030212065A1 (en) 2003-11-13
AR031152A1 (es) 2003-09-10
AU2002211226A1 (en) 2002-05-15
MXPA03003912A (es) 2004-09-10
US20020107257A1 (en) 2002-08-08
WO2002036123A2 (fr) 2002-05-10
CA2421705A1 (fr) 2002-05-10
CN1606442A (zh) 2005-04-13
US6716854B2 (en) 2004-04-06
WO2002036123A3 (fr) 2002-09-19
EA200300527A1 (ru) 2003-08-28

Similar Documents

Publication Publication Date Title
US6716854B2 (en) Treatments for restless legs syndrome
AU2001253114B2 (en) Compounds for treating fibromyalgia and chronic fatigue syndrome
US6114326A (en) Use of cabergoline in the treatment of restless legs syndrome
AU2001253114A1 (en) Compounds for treating fibromyalgia and chronic fatigue syndrome
WO1999011252A2 (fr) Chlorure de n,n-bis (phenylcarbamoylmethyl) dimethylammonium et ses derives, servant au traitement de la douleur
US10265309B2 (en) Sublingual opioid formulations containing naloxone
CA2868228C (fr) Traitement de la depression respiratoire
JP2004506621A (ja) 嗜癖障害治療用の化合物
JP2020523300A (ja) キサンチン又はキサンチン誘導体の医薬製剤、及びその使用
WO2006115302A1 (fr) Agent thérapeutique pour la douleur neuropathique
ZA200208273B (en) Compounds for treating fibromyalgia and chronic fatigue syndrome.
MX2014013425A (es) Biodisponibilidad de incrementos de metilnaltrexona oral con una formulacion basada en fosfatidilcolina.
EP1569649A2 (fr) Utilisation de composes heterocycliques de type amine comme agents neuroprotecteurs
JP2005533786A (ja) 不穏下肢症候群を治療するためのドパミン部分作用剤の使用、並びに対応する医薬製剤
EP1477168A1 (fr) Utilisation de la cabergoline pour traiter le syndrome de l'acroparesthésie nocturne